10 biologics process development experts

Split by stage, these biologics process development experts cover upstream cell culture, downstream purification, late-stage development and pilot-scale tech transfer, with titles at GSK, AstraZeneca, Fresenius Kabi, Gilead Sciences, Johnson & Johnson Innovative Medicine, Pfizer, Ultragenyx, Sutro Biopharma and Halozyme. Their work spans monoclonal antibodies, biosimilars, cell therapy and gene therapy, useful when planning a biologic's path from clinic to commercial supply.

10 professionals9 companiesData retrieved October 4, 2026

Professionals to explore

  1. Ajit Smith-Iyer

    LinkedIn

    Experience: Executive Director Upstream Process Development · Sutro Biopharma, Inc.

    $673 per 30-minute call

    Ajit Smith-Iyer holds Executive Director Upstream Process Development at Sutro Biopharma, Inc. (since 2024). At Bayer, Ajit was Sr Director Clinical Manufacturing (2023–2024), Sr Director Director Digital Manufacturing (2017–2023), Group Head Process Technology and Engineering (2012–2017) and Principal Process Engineer (2006–2012). Ajit describes gene therapy work since the late 1990s and experience from early stage clinical development through commercial production, and suits questions on scaling upstream processes into manufacturing.

    Is this you? Claim your profile and get paid for calls.

  2. Edmund Rossi

    LinkedIn

    Experience: Former Executive Director, Process Development · Gilead Sciences

    $1,010 per 30-minute call

    Edmund Rossi was Executive Director, Process Development at Gilead Sciences (2021–2024). At Immunomedics, Edmund held Vice President, Process and Manufacturing Sciences (2018–2020), Vice President, Process Development and Manufacturing (2018), Associate Vice President, Process Development and Manufacturing (2015–2017) and Executive Director, Recombinant Engineering (2011–2014), and cites more than 25 years in cGMP process development and manufacturing of biologics. Edmund suits development-to-manufacturing questions.

    Is this you? Claim your profile and get paid for calls.

  3. Jose Zuniga

    LinkedIn

    Experience: Associate Director Bioprocess Development · Halozyme, Inc.

    $471 per 30-minute call

    Jose Zuniga was Associate Director Bioprocess Development at Halozyme, Inc. (2022–2024) and Bioprocess Development Scientist II there (2019–2022), and has been Associate Director Upstream Biologics at Disc Medicine since 2026. Jose was Senior Manager CMC Cell Culture Manufacturing at Abcuro, Inc (2025–2026) and CMC Senior Principal Process Engineer at Immunovant (2024–2025), and cites leading global CDMO partnerships for monoclonal antibody programs. Jose fits CDMO and upstream questions.

    Is this you? Claim your profile and get paid for calls.

  4. Kevin Clark

    LinkedIn

    Experience: Director Cell Culture Development · Johnson & Johnson Innovative Medicine

    $606 per 30-minute call

    Kevin Clark has been Director Cell Culture Development at Johnson & Johnson Innovative Medicine since 2023 and held a PDMS title there (2014–2023). Kevin was Sr. Manager Upstream Process Development at Patheon (2013–2014), Sr. Manager Upstream Manufacturing & Development (2012–2013) and Manager Cell Culture Process Development (2012) at Laureate Biopharmaceutical Services. Kevin fits questions on cell culture development and on moving upstream processes from development into manufacturing.

    Is this you? Claim your profile and get paid for calls.

  5. Louise Ingram

    LinkedIn

    Experience: Former Director, Downstream Process Development · Fresenius Kabi

    $539 per 30-minute call

    Louise Ingram is Vice President, Process Development and Manufacturing Sciences at Fresenius Kabi SwissBioSim (since 2025) and was Senior Director, Process Development and Manufacturing Sciences (2020–2025), Director, Downstream Process Development (2018–2020) and Head of Downstream Development, Biosimilars (2017–2018) at Fresenius Kabi. Louise cites 23 years in process development, characterisation, validation and transfer for monoclonal antibodies and recombinant proteins. Louise suits biosimilar process questions.

    Is this you? Claim your profile and get paid for calls.

  6. Mahesh V. Bule

    LinkedIn

    Experience: Former Director, Late-Stage Process Development · AstraZeneca

    $673 per 30-minute call

    Mahesh V. Bule became Director, Late-Stage Process Development at AstraZeneca in 2026, after Associate Director and Group Lead at Kite Pharma (2022–2026). Mahesh was Process Development Sr. Scientist (2021–2022) and Process Development Scientist (2018–2021) at Amgen, and describes designing, optimizing and scaling up cell therapy processes for cancer, with upstream and downstream development and process characterization. Mahesh fits late-stage and cell therapy process questions.

    Is this you? Claim your profile and get paid for calls.

  7. Michael Murphy

    LinkedIn

    Experience: Former Senior Scientist - Biologics Process Development (Pilot-Scale & Tech Transfer) · Pfizer

    $269 per 30-minute call

    Michael Murphy was Senior Scientist - Biologics Process Development (Pilot-Scale & Tech Transfer) at Pfizer (2023–2025), where Michael led pilot-scale biologics process development and transfer-readiness work, and Scientist - Biologics Process Development (Pilot-Scale Operations) at Seagen (2021–2023). Michael is now Senior Scientist, Early Bioprocess Research at AstraZeneca (since 2026) and was Mammalian Production Core Lead (Biologics Production & Lab Build-Out) at the Institute for Protein Design, University of Washington (2018–2021). Michael fits pilot-scale questions.

    Is this you? Claim your profile and get paid for calls.

  8. Mukesh Mayani, PhD, P.Eng.

    LinkedIn

    Experience: Senior Director, Purification Development - Global CMC Development · Ultragenyx

    $673 per 30-minute call

    Mukesh Mayani, PhD, P.Eng. is Senior Director, Purification Development - Global CMC Development at Ultragenyx (since 2024), heading and overseeing DS and DP development teams for two BLA submissions, including authoring and reviewing BLA sections and responding to information requests. Mukesh was Director and Head of Process Development, Gene Therapy at Resilience (2022–2024) and Associate Director, Genomic Medicine CMC at Sanofi (2020–2022). Mukesh fits purification and BLA filing questions.

    Is this you? Claim your profile and get paid for calls.

  9. Nicole A. Bleckwenn

    LinkedIn

    Experience: Executive Director · AstraZeneca

    $1,010 per 30-minute call

    Nicole A. Bleckwenn has held Executive Director titles at AstraZeneca since 2022, currently as Executive Director of Upstream Process Development within Biopharmaceutical Development, and was Senior Director at AstraZeneca (2021–2022). Nicole cites 25 years in the biopharmaceutical sector in biologics development and manufacturing. Nicole is the pick for questions on upstream process development for biologics and on how an upstream group fits within biopharmaceutical development.

    Is this you? Claim your profile and get paid for calls.

  10. Ying Yang

    LinkedIn

    Experience: Director, Head of Downstream Process Development & MFG Operations, Strategic External Development · GSK

    $673 per 30-minute call

    Ying Yang has held Director, Head of Downstream Process Development & MFG Operations, Strategic External Development at GSK since 2020, and cites work across process development, pilot operations, technology transfer, clinical and commercial manufacturing support, CDMO management and regulatory submissions. Ying was Associate Director Of Downstream Process Development and Operations at TESARO, Inc. (2017–2020) and Associate Director, Head of US Pilot Plant Operations at Shire (2016–2017). Ying fits downstream and CDMO questions.

    Is this you? Claim your profile and get paid for calls.

Choose the right perspective

Choose by unit operation first: Nicole A. Bleckwenn, Ajit Smith-Iyer, Kevin Clark and Jose Zuniga are the upstream and cell culture picks, while Ying Yang, Louise Ingram and Mukesh Mayani, PhD, P.Eng. cover downstream and purification. For filing and late-stage work, Mukesh Mayani has overseen teams for two BLA submissions and Mahesh V. Bule holds a late-stage title; Michael Murphy fits pilot-scale tech transfer, and Edmund Rossi fits questions spanning development and manufacturing.

Questions to take into the conversation

  1. 01At what clinical stage should a biologics team lock its cell line and upstream process, and what changes are still safe after that point?
  2. 02How do you plan process characterization so a monoclonal antibody process is ready for validation and a BLA filing?
  3. 03What has to be in place before transferring a biologics process from in-house pilot scale to a CDMO for clinical or commercial manufacturing?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Other perspectives in Biotechnology